Cd133/2. 130-090-854 CD1332 293C3-APC human monoclonal This product has been discontinued by Miltenyi Biotec but remains here on CiteAb for record purposes. CD133-1 and CD133-2 may be useful in order to select and enrich the population of CD133 ovarian tumor cells which are characterized by a higher clonogenic efficiency and proliferative potential. CD1332 Antibody anti-human APC from Miltenyi Biotec. It reacts with Human. The results indicated that the expression of CD133-1 was positive in 18 cases 375 and expression of CD133. 3 Sloan-Kettering Cancer Center New York New York USA. However the use of CD133 as a marker for identifying and. Item Anti-CD1332 293C3-APC human. Anti-CD1332 293C3-APC human from Miltenyi Biotec. CD133-2-expressing cells similar to those found in pri- In conclusion we documented that CD133-1 and mary ovarian cancer. AC133 is frequently used to isolate CSCs and suggested to recognize a glycosylated epitope on CD133 which contains eight putative N-linked glycosylation sites. CD133 is a 97-kDa glycoprotein with five transmembrane domains binds to the cell membrane cholesterol and is associated with a particular membrane microdomain in a cholesterol-dependent manner. The CD1332 Antibody anti-human APC was generated using PROM1 as the antigen. 2 Regeneron Pharmaceuticals Inc Tarrytown New York USA.
The Rational Development Of Cd133 Targeting Immunotherapies For Glioblastoma Sciencedirect
We previously reported that a commercially available antibody against CD133 CD133-2AC141 also. The aims of this study were to investigate the expression of the CD133-1 and CD133-2 epitopes in primary ovarian tumors and to biologically characterize CD133 ovarian cancer cells also according to clinicopathologic parameters. Cd133 2 apc conjugated antibody. CD133-2-expressing cells similar to those found in pri- In conclusion we documented that CD133-1 and mary ovarian cancer. Expression of CD133-1 and CD133-2 in 48 cases of B-ALL and 25 cases at initial diagnosis and the 33rd day of treatment was detected by flow cytometry. 130-090-854 CD1332 293C3-APC human monoclonal This product has been discontinued by Miltenyi Biotec but remains here on CiteAb for record purposes. A promising target for preventing progression of TNBC. CD133 is a marker that is frequently found on multipotent progenitor cells including immature hematopoietic stem and progenitor cells in human fetal liver bone marrow cord blood and peripheral blood. The most commonly used are AC133 CD1331 and 293CAC141 CD1332 which are reported to recognize distinct epitopes. Eight normal ovaries and five.
Cd133/2 Biocompare is the leading resource for up-to-date product information product reviews and new technologies for life scientists.
Cd133/2. 1 Howard Hughes Medical Institute Ansary Center for Stem Cell Therapeutics and Department of Genetic Medicine Weill Medical College of Cornell University New York New York USA. The most commonly used are AC133 CD1331 and 293CAC141 CD1332 which are reported to recognize distinct epitopes. CD133 has also been found to be expressed on circulating endothelial progenitor cells tissue-specific stem cells. 1 Howard Hughes Medical Institute Ansary Center for Stem Cell Therapeutics and Department of Genetic Medicine Weill Medical College of Cornell University New York New York USA. CD1332 293C3-APC human monoclonal. 3 Sloan-Kettering Cancer Center New York New York USA. Minimal residual disease MRD of B-ALL at 33rd day was evaluated by flow cytometry. CD133-1 and CD133-2 may be useful in order to select and enrich the population of CD133 ovarian tumor cells which are characterized by a higher clonogenic efficiency and proliferative potential. This product has been discontinued by Miltenyi Biotec but remains here on CiteAb for record purposes. In order to further explore the physiological and pathological functions of CD133-2 we generated two mouse antihuman CD133-2 monoclonal antibodies clones 6B3 and 9G4. This antibody has been shown to work in applications such as. CD1332 Antibody anti-human APC from Miltenyi Biotec. It reacts with Human. Biocompare is the leading resource for up-to-date product information product reviews and new technologies for life scientists.
Cd133/2. 3 Sloan-Kettering Cancer Center New York New York USA. Whether the two isoforms are functionally redundant or serve distinct functions remains unclear. This product has been discontinued by Miltenyi Biotec but remains here on CiteAb for record purposes. CD1332 Antibody anti-human APC from Miltenyi Biotec. Cd133 2 apc conjugated antibody. The aims of this study were to investigate the expression of the CD133-1 and CD133-2 epitopes in primary ovarian tumors and to biologically characterize CD133 ovarian cancer cells also according to clinicopathologic parameters. 1 Howard Hughes Medical Institute Ansary Center for Stem Cell Therapeutics and Department of Genetic Medicine Weill Medical College of Cornell University New York New York USA. It reacts with Human. Page 1 of 1. A promising target for preventing progression of TNBC. The results indicated that the expression of CD133-1 was positive in 18 cases 375 and expression of CD133. AC133 has two isoforms one is AC133-1 and the other is AC133-2.
130-090-854 CD1332 293C3-APC human monoclonal This product has been discontinued by Miltenyi Biotec but remains here on CiteAb for record purposes. CD133 Prominin I a cell-surface antigen is the first in a class of pentaspan membrane proteins. CD133 is an antigen expressed on hematopoietic progenitor cells and on some epithelial cells. CD133 has also been found to be expressed on circulating endothelial progenitor cells tissue-specific stem cells. Miltenyi Biotecs CD1332 Antibody anti-human APC is a Mouse monoclonal antibody. CD133 is a 97-kDa glycoprotein with five transmembrane domains binds to the cell membrane cholesterol and is associated with a particular membrane microdomain in a cholesterol-dependent manner. Biocompare is the leading resource for up-to-date product information product reviews and new technologies for life scientists. Clone REAL233 is an antibody fragment derived from the full CD133 1 antibody molecule It displays no binding to Fc receptors The recombinantly engineered antibody fragments are multimerized to form the REAlease Complex to bind markers with high avidity Clone REAL233 recognizes the epitope 1. 2 Regeneron Pharmaceuticals Inc Tarrytown New York USA.
Cd133/2 CD1332 293C3-APC human monoclonal.
A promising target for preventing progression of TNBC. Cd133/2 Indeed also in benign prostate CD133-2 may be useful in order to select and enrich CD1331 cells have been documented and shown to the population of CD133-expressing ovarian tumor exhibit extensive proliferation in vitro. The CD1332 Antibody anti-human APC was generated using PROM1 as the antigen. 130-090-854 CD1332 293C3-APC human monoclonal This product has been discontinued by Miltenyi Biotec but remains here on CiteAb for record purposes. This antibody has been shown to work in applications such as. 1 Howard Hughes Medical Institute Ansary Center for Stem Cell Therapeutics and Department of Genetic Medicine Weill Medical College of Cornell University New York New York USA. Expression of CD133-1 and CD133-2 in 48 cases of B-ALL and 25 cases at initial diagnosis and the 33rd day of treatment was detected by flow cytometry. AC133 is frequently used to isolate CSCs and suggested to recognize a glycosylated epitope on CD133 which contains eight putative N-linked glycosylation sites. We previously reported that a commercially available antibody against CD133 CD133-2AC141 also. CD133 has also been found to be expressed on circulating endothelial progenitor cells tissue-specific stem cells. Clone REA816 recognizes epitope 2 of the human CD133 antigen CD1332. Eight normal ovaries and five. CD133-2-expressing cells similar to those found in pri- In conclusion we documented that CD133-1 and mary ovarian cancer. Minimal residual disease MRD of B-ALL at 33rd day was evaluated by flow cytometry.
